



Editorial Changes—Report No. 18

1 July 2024–31 December 2024

1 In preparing compilations for registration during the above period, First Parliamentary Counsel made the following editorial changes under the *Legislation Act 2003*.

2 The summary of editorial changes for the 61 compilations affected is as follows:

Item	Kind of editorial change	Number
1	Changes to capitalisation	1
2	Changes to grammar, syntax or the use of conjunctives or disjunctives	3
3	Changes to punctuation	10
4	Changes to spelling	1
5	Changes to typeface	1
6	Correct errors arising out of an amendment of an instrument	1
7	Correct typographical errors	3
8	Give effect to the misdescribed amendments as intended	39
9	Numbering or renumbering of provisions	6
10	Removal of redundant text	10
11	Reordering of definitions	5
12	Updates to references of a law or a provision	3
13	Updates to references to a person, body or other entity, or an office, position, place, document or thing	2

3 Please note that each instance of the power being used in a compilation is counted. This means that for a number of compilations the power has been used multiple times (for example, to correct typographical errors in different sections of the same compilation).

4 Complete details of each use of the power within a compilation appears below:

Taxation Administration Act 1953, Compilation No. 215, Registration Date: 24 December 2024 [C2024C00863]

Subsection 444-30(5) of Schedule 1 (second occurring)

Kind of editorial change

Numbering or renumbering of provisions

Details of editorial change

Schedule 1 item 62 of the *Treasury Laws Amendment (Multinational—Global and Domestic Minimum Tax) (Consequential) Act 2024* instructs to add subsection 444-30(5) at the end of section 444-30 in Schedule 1.

However, a subsection 444-30(5) already appears in section 444-30 of Schedule 1.

This compilation was editorially changed by renumbering the newly inserted, second occurring subsection 444-30(5) of Schedule 1 as subsection 444-30(6) of Schedule 1.

Online Safety Act 2021, Compilation No. 3, Registration Date: 21 December 2024 [C2024C00852]

Section 222A

Kind of editorial change

Give effect to the misdescribed amendment as intended

Details of editorial change

Schedule 1 item 13A of the *Online Safety Amendment (Social Media Minimum Age) Act 2024* provides as follows:

13A After section 222

222A Liability for damages—Information Commissioner

The Information Commissioner is not liable to an action or other proceeding for damages for, or in relation to, an act or matter in good faith done or omitted to be done:

- (a) in the performance or purported performance of any function; or
 - (b) in the exercise or purported exercise of any power;
- conferred on the Information Commissioner by or under this Act.

The instruction to insert the section is missing.

This compilation was editorially changed to insert section 222A after section 222 to give effect to the misdescribed amendment as intended.

List of CITES Species for the Purposes of the Act, Compilation No. 29, Registration Date: 20 December 2024 [F2024C01275]

Kind of editorial change

Give effect to the misdescribed amendment as intended

Details of editorial change

Schedule 1 of the *List of CITES Species Amendment (2024/094) Instrument 2024* provides as follows:

Schedule 1—Amendments

List of CITES Species Amendment (2024/094) Instrument

The title to be amended reads “*List of CITES Species Amendment (2024/094) Instrument*” rather than the correct title of “*List of CITES Species for the Purposes of the Act*”.

This compilation was editorially changed by applying the amendment from Schedule 1 of the *List of CITES Species Amendment (2024/094) Instrument 2024* to the *List of CITES Species for the Purposes of the Act* to give effect to the misdescribed amendment as intended.

Telecommunications (Designated Service Area and Statutory Infrastructure Provider) Declaration (No. 1) 2020, Compilation No. 9, Registration Date: 20 December 2024 [F2024C01280]

Section 4

Kind of editorial change

Removal of redundant text

Details of editorial change

Schedule 1 item 1 of the *Telecommunications (Designated Service Area and Statutory Infrastructure Provider) Amendment Declaration (No. 1) 2024* instructs to repeal various definitions from subsection 4(1) and to repeal subsection 4(2).

Section 4 appears, in part, as follows:

4 Interpretation

[...]

(1) In this instrument:

Act means the *Telecommunications Act 1997*.

Advatel Wireless Pty Ltd means Advatel Wireless Pty Ltd (ACN 107 934 305), as the company exists from time to time (even if its name is later changed).

[...]

This compilation was editorially changed to omit “(1)” from section 4 to remove the redundant text and bring it into line with legislative drafting practice.

Schedule 16A

Kind of editorial change

Removal of redundant text

Details of editorial change

Schedule 1 item 11 of the *Telecommunications (Designated Service Area and Statutory Infrastructure Provider) Amendment Declaration (No. 1) 2024* appears as follows:

11 Schedule 16A

Repeal the table.

This amendment results in Schedule 16A containing only a Schedule heading and a table heading.

This compilation was editorially changed to omit the redundant Schedule 16A heading and table heading.

Competition and Consumer Act 2010, Compilation No. 156, Registration Date: 19 December 2024 [C2024C00827]

Subsection 134(2) of Schedule 2

Kind of editorial change

Give effect to the misdescribed amendment as intended

Details of editorial change

Schedule 2 item 14 of the *Treasury Laws Amendment (Fairer for Families and Farmers and Other Measures) Act 2024* provides as follows:

14 At the end of subsection 134(2) of Schedule 2

- ; (g) require the making and keeping of records in relation to goods or services of that kind;
- (h) require the provision of information to any person, including the regulator, in relation to goods or services of that kind.

The instruction to insert the paragraphs is missing.

This compilation was editorially changed to insert paragraphs 134(2)(g) and (h) at the end of subsection 134(2) of Schedule 2 to give effect to the misdescribed amendment as intended.

Identity Verification Services Act 2023, Compilation No. 1, Registration Date: 19 December 2024 [C2024C00830]

Paragraph 9(1)(e)

Kind of editorial change

Update to a reference of a law or a provision

Details of editorial change

Paragraph 9(1)(e) contains a reference to the *Privacy Act 1993* of New Zealand instead of the *Privacy Act 2020* of New Zealand.

This compilation was editorially changed to update a reference from the *Privacy Act 1993* of New Zealand to the *Privacy Act 2020* of New Zealand in paragraph 9(1)(e).

**Offshore Petroleum and Greenhouse Gas Storage Act 2006,
Compilation No. 58, Registration Date: 19 December 2024
[C2024C00828]**

Subsection 640(3) (paragraph (a) of the definition of *Commonwealth maritime legislation*)

Kind of editorial change

Give effect to the misdescribed amendment as intended

Details of editorial change

Schedule 2 item 3 of the *Offshore Petroleum and Greenhouse Gas Storage Legislation Amendment (Safety and Other Measures) Act 2024* instructs to add the following text “, other than section 342A of that Act” at the end of paragraph (a) of the definition of *Commonwealth maritime legislation* in subsection 640(3).

However, at the end of paragraph (a) of the definition of *Commonwealth maritime legislation* there is a semicolon and the word “and”.

This compilation was editorially changed to insert the text “, other than section 342A of that Act” after the text “the *Navigation Act 2012*” in paragraph (a) of the definition of *Commonwealth maritime legislation* in subsection 640(3) to give effect to the misdescribed amendment as intended.

**Social Security Act 1991, Compilation No. 223, Registration Date:
16 December 2024 [C2024C00805]**

Subsection 1061ZZET(1)

Kind of editorial change

Change to punctuation

Details of editorial change

Schedule 1 item 36 of the *Universities Accord (Student Support and Other Measures) Act 2024* provides as follows:

36 Subsection 1061ZZET(1)

Omit “worked out using the following Method statement”, substitute “the lower of the CPI indexation factor for the relevant year (see subsection (1A)) and the WPI indexation factor for the relevant year (see subsection (1B)).”.

This amendment results in two full stops at the end of subsection 1061ZZET(1).

This compilation was editorially changed to omit the extra full stop at the end of subsection 1061ZZET(1) to correct the punctuation.

Freedom of Information Act 1982, Compilation No. 116, Registration Date: 13 December 2024 [C2024C00802]

Subsections 61A(3) and 62(1)

Kind of editorial change

Correct typographical errors

Details of editorial change

Subsections 61A(3) and 62(1) refer to “*Administrative Appeals Review Act 2024*” rather than “*Administrative Review Tribunal Act 2024*”.

This compilation was editorially changed to omit “*Administrative Appeals Review Act 2024*” and substitute “*Administrative Review Tribunal Act 2024*” in subsections 61A(3) and 62(1) to correct the typographical errors.

Migration Act 1958, Compilation No. 163, Registration Date: 13 December 2024 [C2024C00800]

Paragraphs 347A(1)(b)–(d)

Kind of editorial change

Removal of redundant text

Details of editorial change

Subsection 347A(1) appears as follows:

- (1) An application for review of a reviewable migration decision may only be made by:
 - (a) for a decision covered by subsection 338(2), (3), (3A), (4) or (7A)—the non-citizen who is the subject of that decision; or
 - (b) for a decision covered by subsection 338(5) or (8)—by the sponsor or nominator referred to in the subsection concerned; or
 - (c) for a decision covered by subsection 338(6) or (7)—by the relative referred to in the subsection concerned; or
 - (d) for a decision covered by subsection 338(9)—by the person prescribed in respect of the kind of decision in question prescribed for the purposes of that subsection.

Note: Section 5G may be relevant for determining family relationships for the purposes of paragraph (c) of this subsection.

The chapeau to subsection 347A(1) ends with the word “by”. Paragraphs 347A(1)(b)–(d) each contain an erroneous duplication of the word “by” (second occurring).

This compilation was editorially changed to omit “by” (second occurring) from paragraphs 347A(1)(b)–(d) to remove the redundant text.

Paragraph 474(7)(a)

Kind of editorial change

Change to grammar, syntax or the use of conjunctives or disjunctives and change to punctuation

Details of editorial change

Schedule 1 item 4 of the *Migration Amendment (Removal and Other Measures) Act 2024* instructs to insert “199G,” before “351” in paragraph 474(7)(a).

Paragraph 474(7)(a) reads as follows:

- (a) a decision of the Minister not to exercise, or not to consider the exercise, of the Minister’s power under subsection 37A(2) or (3), section 48B, paragraph 72(1)(c), section 91F, 91L, 91Q, 195A, 197AB, 197AD, 198AE or 199G, 351 or subsection 503A(3);

This compilation was editorially changed to omit “or 199G,” and substitute “, 199G or” to correct the grammar and punctuation.

National Health (Immunisation Program — Designated Vaccines) Determination 2014 (No.1), Compilation No. 27, Registration Date: 13 December 2024 [F2024C01228]

Paragraph 7(9A)(aa)

Kind of editorial change

Change to punctuation

Details of editorial change

Schedule 1 item 1 of the *National Health (Immunisation Program – Designated Vaccines) Amendment Determination (No. 2) 2024* provides as follows:

1 Before paragraph 7(9A)(a)

Insert:

- (aa) a child who is at least 6 months of age but less than 5 years of age; or.

Paragraph 7(9A)(aa) ends in a full stop despite being followed by paragraph (a).

This compilation was editorially changed to omit the full stop at the end of paragraph 7(9A)(aa) to bring it into line with legislative drafting practice.

Part 2 of Schedule 1

Kind of editorial change

Removal of redundant text

Details of editorial change

Schedule 1 item 6 of the *National Health (Immunisation Program – Designated Vaccines) Amendment Determination (No. 2) 2024* provides as follows:

6 In the appropriate position in Part 2 of Schedule 1 (table)

Insert:

Item	Vaccine and the circumstances in which vaccine may be provided	Brand	Formulation	Active ingredient and strength	Number and timing of doses
222	Vaccine respiratory syncytial virus (RSV) stabilised prefusion F subunit Circumstances Vaccine may be provided to a person who is pregnant	Abrysvo	Injection (0.5mL)	Each 0.5mL dose contains 120 µg of stabilised prefusion F proteins (60 µg RSV-A and 60 µg RSV-B antigens)	1 dose: (a) at 28 to 36 weeks gestation; or (b) after 36 weeks gestation, if vaccination is two weeks prior to birth.

This amendment results in two occurrences of the table column headings in the table.

This compilation was editorially changed to omit the second occurrence of the table column headings from Part 2 of Schedule 1 to remove the redundant text.

National Health (Listing of Pharmaceutical Benefits) Instrument 2024 (PB 26 of 2024), Compilation No. 7, Registration Date: 10 December 2024 [F2024C01200]

Kind of editorial change

Give effect to the misdescribed amendments as intended

Details of editorial change

Schedule 1 items 3–7, 12–16, 22, 23, 31, 57–61, 64, 65, 74, 129, 130, 147, 148, 217, 219, 236, 237, 270–273 and 276 of the *National Health (Listing of Pharmaceutical Benefits) Amendment (November Update) Instrument 2024* (PB 111 of 2024) instruct to amend or omit the entry, the location of which is specified by reference to the drug's form, brand, maximum quantity and number of repeats. However, there are multiple entries in the locations specified.

This compilation was editorially changed to apply the amendments to the entries listed in the table below to give effect to the misdescribed amendments as intended.

Amending provision	Principal provision Schedule 1, Part 1
3	Amitriptyline in the form Tablet containing amitriptyline hydrochloride 10 mg <i>[Brand: APO-Amitriptyline 10]</i>
4	Amitriptyline in the form Tablet containing amitriptyline hydrochloride 25 mg <i>[Brand: APO-Amitriptyline 25]</i>
5	Amitriptyline in the form Tablet containing amitriptyline hydrochloride 50 mg <i>[Brand: APO-Amitriptyline 50]</i>
6	Amlodipine in the form Tablet 5 mg (as besilate) <i>[Brand: BTC Amlodipine]</i>
7	Amlodipine in the form Tablet 10 mg (as besilate) <i>[Brand: BTC Amlodipine]</i>
12	Atenolol in the form Tablet 50 mg <i>[Brand: APO-Atenolol]</i>
13	Atorvastatin in the form Tablet 10 mg (as calcium) <i>[Brand: Blooms the Chemist Atorvastatin]</i>
14	Atorvastatin in the form Tablet 20 mg (as calcium) <i>[Brand: Blooms the Chemist Atorvastatin]</i>
15	Atorvastatin in the form Tablet 40 mg (as calcium) <i>[Brand: Blooms the Chemist Atorvastatin]</i>
16	Atorvastatin in the form Tablet 80 mg (as calcium) <i>[Brand: Blooms the Chemist Atorvastatin]</i>
22	Bosentan in the form Tablet 62.5 mg (as monohydrate) <i>[Brand: BOSLEER]</i>
23	Bosentan in the form Tablet 125 mg (as monohydrate) <i>[Brand: BOSLEER]</i>
31(a)	Calcitriol in the form Capsule 0.25 microgram <i>[Brand: APO-Calcitriol]</i>
31(b)	Calcitriol in the form Capsule 0.25 microgram <i>[Brand: Kosteol]</i>
57	Diazepam in the form Tablet 2 mg <i>[Brand: APO-Diazepam]</i>
58	Diazepam in the form Tablet 5 mg <i>[Brand: APO-Diazepam]</i>
59	Diclofenac in the form Tablet (enteric coated) containing diclofenac sodium 25 mg <i>[Brand: APO-Diclofenac]</i>
60	Diclofenac in the form Tablet (enteric coated) containing diclofenac sodium 50 mg <i>[Brand: APO-Diclofenac]</i>
61	Digoxin in each of the forms: Paediatric oral solution 50 micrograms per mL, 60 mL; Tablet 62.5 micrograms; and Tablet 250 micrograms
64	Entecavir in the form Tablet 0.5 mg (as monohydrate) <i>[Brand: ENTECLUDE]</i>
65	Entecavir in the form Tablet 1 mg (as monohydrate) <i>[Brand: ENTECLUDE]</i>
74	Estradiol and estradiol with dydrogesterone in each of the forms: Pack containing 14 tablets estradiol 1 mg and 14 tablets estradiol 1 mg with dydrogesterone 10 mg; and Pack containing 14 tablets estradiol 2 mg and 14 tablets estradiol 2 mg with dydrogesterone 10 mg
129	Flecainide in the form Tablet containing flecainide acetate 50 mg
130	Flecainide in the form Tablet containing flecainide acetate 100 mg
147	Before first entry for Imatinib in the form Capsule 400 mg (as mesilate)
148	Insulin neutral with insulin isophane in the form Injections (human), cartridges, 30 units-70 units per mL, 3 mL, 5 <i>[Brand: Mixtard 30/70 Penfill 3 mL]</i>
217	First to fourth entries for Pioglitazone in the form Tablet 30 mg (as hydrochloride)
219	First to fourth entries for Pioglitazone in the form Tablet 45 mg (as hydrochloride)
236	First and second entries for Quinapril in the form Tablet 10 mg (as hydrochloride)
237	First and second entries for Quinapril in the form Tablet 20 mg (as hydrochloride)
270	Second entry for Sevelamer in the form Tablet containing sevelamer carbonate 800 mg <i>[Brand: ARX-SEVELAMER; Maximum Quantity: 360; Number of Repeats: 5]</i>

Amending provision	Principal provision Schedule 1, Part 1
271	Second entry for Sevelamer in the form Tablet containing sevelamer carbonate 800 mg [<i>Brand: Sevelamer Apotex; Maximum Quantity: 360; Number of Repeats: 5</i>]
272	Second entry for Sevelamer in the form Tablet containing sevelamer carbonate 800 mg [<i>Brand: Sevelamer Lupin; Maximum Quantity: 360; Number of Repeats: 5</i>]
273	First entry for Sevelamer in the form Tablet containing sevelamer hydrochloride 800 mg [<i>Brand: Renagel; Maximum Quantity: 360; Number of Repeats: 5</i>]
276	Second entry for Tamoxifen [<i>Brand: Genox 20; Maximum Quantity: 60; Number of Repeats: 5</i>]

National Health (Price and Special Patient Contribution) Determination 2022 (PB 98 of 2022), Compilation No. 22, Registration Date: 26 November 2024 [F2024C01165]

Schedule 1, entry for Olmesartan with amlodipine

Kind of editorial change

Give effect to the misdescribed amendment as intended

Details of editorial change

Schedule 1 item 4 of the *National Health (Price and Special Patient Contribution) Amendment Determination 2024 (No. 9)* (PB 120 of 2024) instructs to omit and substitute the entry for Olmesartan with amlodipine in Schedule 1.

The text contained in the column headed “**Form**” does not exactly match the text to be omitted as outlined in Schedule 1 item 4 of the *National Health (Price and Special Patient Contribution) Amendment Determination 2024 (No. 9)* (PB 120 of 2024).

This compilation was editorially changed to omit and substitute the entry for Olmesartan with amlodipine in Schedule 1 to give effect to the misdescribed amendment as intended.

Private Health Insurance (Medical Devices and Human Tissue Products) Rules (No. 2) 2024, Compilation No. 1, Registration Date: 25 November 2024 [F2024C01155]

Schedule 1

Kind of editorial change

Give effect to the misdescribed amendment as intended

Details of editorial change

Schedule 1 item 1 of the *Private Health Insurance (Medical Devices and Human Tissue Products) Amendment (No. 3) Rules 2024* provides as follows:

1 Schedule 1

Repeal the Schedule 1, substitute: the updated Schedule 1 – Listed medical devices and human tissue products.

There is no “Schedule 1 – Listed medical devices and human tissue products” to be substituted in the amending legislation. However, there is a “Schedule”.

This compilation was editorially changed to repeal Schedule 1 and substitute the Schedule to give effect to the misdescribed amendment as intended.

Schedule 1

Kind of editorial change

Numbering or renumbering of provisions

Details of editorial change

Schedule 1 item 1 of the *Private Health Insurance (Medical Devices and Human Tissue Products) Amendment (No. 3) Rules 2024* repealed Schedule 1 and substituted the Schedule.

However, the cross-references in this instrument are to Schedule 1.

This compilation was editorially changed by renumbering the Schedule as Schedule 1.

Health Insurance (Section 3C Midwife and Nurse Practitioner Services) Determination 2020, Compilation No. 12, Registration Date: 22 November 2024 [F2024C01153]

Paragraph 20A(1)(d)

Kind of editorial change

Change to spelling

Details of editorial change

Schedule 1 item 6 of the *Health Insurance (Section 3C Midwife and Nurse Practitioner Services) Amendment (No. 1) Determination 2024* instructs to insert section 20A after section 20.

The newly inserted paragraph 20A(1)(d) refers to “copentency” rather than “competency”.

This compilation was editorially changed to omit “copentency” and substitute “competency” in paragraph 20A(1)(d) to correct the spelling.

National Health (Listing of Pharmaceutical Benefits) Instrument 2024 (PB 26 of 2024), Compilation No. 6, Registration Date: 14 November 2024 [F2024C01115]

Kind of editorial change

Give effect to the misdescribed amendments as intended

Details of editorial change

Schedule 1 items 1, 13, 14, 26–30, 32, 34, 35, 40, 41, 51, 52, 54–58, 62–64, 69, 70, 84, 96, 99, 103, 104, 121–123, 147, 189, 196, 200 and 207 of the *National Health (Listing of Pharmaceutical Benefits) Amendment (October Update) Instrument 2024* (PB 95 of 2024) instruct to omit the entry for a form or brand of a drug. However, multiple entries of these forms or brands of drugs exist.

This compilation was editorially changed to apply the amendments to the entries listed in the table below to give effect to the misdescribed amendments as intended.

Amending provision	Principal provision Schedule 1, Part 1
1	Abacavir with lamivudine in the form Tablet containing abacavir 600 mg (as sulfate) with lamivudine 300 mg [Brand: ABACAVIR/LAMIVUDINE 600/300 SUN]
13	Adalimumab in the form Injection 40 mg in 0.8 mL pre-filled pen [Brand: Idacio]
14	Adalimumab in the form Injection 40 mg in 0.8 mL pre-filled syringe [Brand: Idacio]
26	Aripiprazole in the form Tablet 10 mg [Brand: Tevaripiprazole]
27	Aripiprazole in the form Tablet 15 mg [Brand: Tevaripiprazole]
28	Aripiprazole in the form Tablet 20 mg [Brand: Tevaripiprazole]
29	Aripiprazole in the form Tablet 30 mg [Brand: Tevaripiprazole]
30	Atorvastatin in the form Tablet 80 mg (as calcium) [Brand: Atorvastatin GH]
32	Azithromycin in the form Tablet 500 mg (as dihydrate) [Brand: Azithromycin Mylan]
34	Bendamustine in the form Powder for injection containing bendamustine hydrochloride 25 mg [Brand: Ribomustin]
35	Bendamustine in the form Powder for injection containing bendamustine hydrochloride 100 mg [Brand: Ribomustin]
40	Budesonide with formoterol in the form Powder for oral inhalation in breath actuated device containing budesonide 200 micrograms with formoterol fumarate dihydrate 6 micrograms per dose, 120 doses [Brand: BiResp Spiromax]
41	Budesonide with formoterol in the form Powder for oral inhalation in breath actuated device containing budesonide 400 micrograms with formoterol fumarate dihydrate 12 micrograms per dose, 60 doses [Brand: BiResp Spiromax]
51	Ciprofloxacin in the form Tablet 500 mg (as hydrochloride) [Brand: Cifran]
52	Cyproterone in the form Tablet containing cyproterone acetate 50 mg [Brand: Pharmacor Cyproterone 50]
54	Dabigatran etexilate in the form Capsule 75 mg (as mesilate) [Brand: PHARMACOR DABIGATRAN]
55	Dasatinib in the form Tablet 20 mg [Brand: TE-DASATINIB]
56	Dasatinib in the form Tablet 50 mg [Brand: TE-DASATINIB]
57	Dasatinib in the form Tablet 70 mg [Brand: TE-DASATINIB]
58	Dasatinib in the form Tablet 100 mg [Brand: TE-DASATINIB]

Amending provision	Principal provision Schedule 1, Part 1
62	Dicloxacillin in the form Capsule 500 mg (as sodium) [<i>Brand: Dicloxacillin Mylan 500</i>]
63	Donepezil in the form Tablet containing donepezil hydrochloride 5 mg [<i>Brand: NOUMED DONEPEZIL</i>]
64	Donepezil in the form Tablet containing donepezil hydrochloride 10 mg [<i>Brand: NOUMED DONEPEZIL</i>]
69	Enalapril in the form Tablet containing enalapril maleate 20 mg [<i>Brand: Enalapril generichealth</i>]
70	Entecavir in the form Tablet 0.5 mg (as monohydrate) [<i>Brand: Entecavir Mylan</i>]
84	Esomeprazole in the form Tablet (enteric coated) 20 mg (as magnesium trihydrate) [<i>Brand: NOUMED ESOMEPRAZOLE</i>]
96	Esomeprazole in the form Tablet (enteric coated) 40 mg (as magnesium trihydrate) [<i>Brand: NOUMED ESOMEPRAZOLE</i>]
99	Fluoxetine in the form Capsule 10 mg (Medreich) (S19A)
103	Gabapentin in the form Capsule 300 mg [<i>Brand: Gabapentin generichealth</i>]
104	Gabapentin in the form Capsule 400 mg [<i>Brand: Gabapentin generichealth</i>]
121	Lisinopril in the form Tablet 20 mg [<i>Brand: Lisinopril generichealth</i>]
122	Meloxicam in the form Tablet 7.5 mg [<i>Brand: Pharmacor Meloxicam 7.5</i>]
123	Meloxicam in the form Tablet 15 mg [<i>Brand: Pharmacor Meloxicam 15</i>]
147	Oxaliplatin in the form Solution concentrate for I.V. infusion 100 mg in 20 mL [<i>Brand: Oxaliplatin SUN</i>]
189(a)	Rizatriptan in the form Tablet (orally disintegrating) 10 mg (as benzoate) [<i>Brand: APO-Rizatriptan</i>]
189(b)	Rizatriptan in the form Tablet (orally disintegrating) 10 mg (as benzoate) [<i>Brand: Rizatriptan ODT GH</i>]
196	Tenofovir with emtricitabine in the form Tablet containing tenofovir disoproxil phosphate 291 mg with emtricitabine 200 mg
200	Valaciclovir in the form Tablet 500 mg (as hydrochloride) [<i>Brand: Valacor 500</i>]
207	Zoledronic acid in the form Solution for I.V. infusion 5 mg (as monohydrate) in 100 mL [<i>Brand: Zoledronic Acid SUN</i>]

Telecommunications (Interception and Access) Act 1979, Compilation No. 128, Registration Date: 12 November 2024 [C2024C00749]

Subparagraph 157(2)(p)(ii) of Schedule 1

Kind of editorial change

Change to grammar, syntax or the use of conjunctives or disjunctives

Details of editorial change

Schedule 5 item 193 of the *Crimes and Other Legislation Amendment (Omnibus No. 1) Act 2024* instructs to add paragraph (q) at the end of subclause 157(2) of Schedule 1.

The word “and” is missing at the end of subparagraph 157(2)(p)(ii) of Schedule 1.

This compilation was editorially changed to insert the word “and” at the end of subparagraph 157(2)(p)(ii) of Schedule 1 to bring it into line with legislative drafting practice.

Telecommunications (Interception and Access) Regulations 2017, Compilation No. 11, Registration Date: 12 November 2024 [F2024C01110]

Forms 1 to 5D in Schedule 1

Kind of editorial change

Correct an error arising out of an amendment of an instrument

Details of editorial change

Forms 1 to 5D in Schedule 1 contain references to “*nominated AAT member”.

This compilation was editorially changed to update references by omitting “*nominated AAT member” and substituting “*nominated ART member” in Forms 1 to 5D of Schedule 1.

Health Insurance (General Medical Services Table) Regulations 2021, Compilation No. 17, Registration Date: 8 November 2024 [F2024C01086]

Subclause 2.22.1(3) of Schedule 1

Kind of editorial change

Give effect to the misdescribed amendment as intended

Details of editorial change

Schedule 2 item 6 of the *Health Insurance Legislation Amendment (2024 Measures No. 4) Regulations 2024* provides as follows:

6 Subclauses 2.22.1(3) and (4) of Schedule 1

Omit “729”, substitute “792”.

The number “729” appears twice in subclause 2.22.1(3) of Schedule 1.

This compilation was editorially changed to omit “729” (wherever occurring) and substitute “792” in subclause 2.22.1(3) of Schedule 1 to give effect to the misdescribed amendment as intended.

Proceeds of Crime Regulations 2019, Compilation No. 3, Registration Date: 6 November 2024 [F2024C01069]

Section 18

Kind of editorial change

Removal of redundant text

Details of editorial change

Schedule 2 item 37 of the *Administrative Review Tribunal Legislation Consequential Amendments (2024 Measures No. 1) Regulations 2024* instructs to repeal subsection 18(1).

Section 18 appears as follows:

18 Approved examiners

- (2) For the purposes of paragraph 183(5)(a) of the Act, the following classes of people are specified:
 - (a) persons who have held the office of judge in the Supreme Court, District Court or County Court of a State or Territory and have stated, in writing, that they are willing to be an approved examiner;
 - (b) persons who have held the office of magistrate and have stated, in writing, that they are willing to be an approved examiner.

This compilation was editorially changed to omit “(2)” from section 18 to remove the redundant text and bring it into line with legislative drafting practice.

Hearing Services Program (Voucher) Instrument 2019, Compilation No. 4, Registration Date: 4 November 2024 [F2024C01057]

Section 7 (heading)

Kind of editorial change

Give effect to the misdescribed amendment as intended

Details of editorial change

Schedule 1 item 1 of the *Hearing Services Program (Voucher) Amendment (Administrative Review Tribunal and Other Matters) Instrument 2024* provides as follows:

1 Section 7 (heading)

Omit “**Dependents**”, substitute “**Spouses or de facto partners**”.

The word “**Dependents**” does not appear in the heading to section 7. However, the word “**Dependants**” does appear.

This compilation was editorially changed to omit “**Dependants**” and substitute “**Spouses or de facto partners**” in the heading to section 7 to give effect to the misdescribed amendment as intended.

Paragraph 9(b)

Kind of editorial change

Give effect to the misdescribed amendment as intended

Details of editorial change

Schedule 1 item 4 of the *Hearing Services Program (Voucher) Amendment (Administrative Review Tribunal and Other Matters) Instrument 2024* provides as follows:

4 Subsection 9(b)

Omit “, for purposes connected with obtaining treatment for an injury, disease or condition that involves hearing loss, a card that is issued by the Commonwealth and known as a DVA Health Card (White)”, substitute “a card issued by the Commonwealth and known as a Veteran White Card”.

The text “, for purposes connected with obtaining treatment for an injury, disease or condition that involves hearing loss, a card that is issued by the Commonwealth and known as a DVA Health Card (White)” does not appear in paragraph 9(b). However, the text “, for purposes connected with obtaining treatment for an injury, disease or condition that involves hearing loss, a card issued by the Commonwealth and known as a DVA Health Card (White)” does appear.

This compilation was editorially changed to omit “, for purposes connected with obtaining treatment for an injury, disease or condition that involves hearing loss, a card issued by the Commonwealth and known as a DVA Health Card (White)” and substitute “a card issued by the Commonwealth and known as a Veteran White Card” in paragraph 9(b) to give effect to the misdescribed amendment as intended.

Section 28

Kind of editorial change

Give effect to the misdescribed amendment as intended

Details of editorial change

Schedule 1 item 8 of the *Hearing Services Program (Voucher) Amendment (Administrative Review Tribunal and Other Matters) Instrument 2024* provides as follows:

8 Section 28

Omit “guidance published on the program’s website”, substitute “schedule of service items and fees”.

The text “guidance published on the program’s website” does not appear in section 28. However, the text “guidance published on the program website” does appear.

This compilation was editorially changed to omit “guidance published on the program website” and substitute “schedule of service items and fees” in section 28 to give effect to the misdescribed amendment as intended.

Health Insurance (Pathology Services Table) Regulations 2020, Compilation No. 15, Registration Date: 1 November 2024 [F2024C01052]

Schedule 1 (cell at item 73451, column 2, paragraph (c))

Kind of editorial change

Update to a reference to a person, body or other entity, or an office, position, place, document or thing

Details of editorial change

Paragraph (c) contains an outdated reference to the FMR1 gene.

This compilation was editorially changed to update a reference in paragraph (c) to the international best practice terminology for the FMR1 gene, determined by the HUGO Gene Nomenclature Committee.

Private Health Insurance (Medical Devices and Human Tissue Products) Rules (No. 1) 2024, Compilation No. 1, Registration Date: 30 October 2024 [F2024C01030]

Schedule 1

Kind of editorial change

Give effect to the misdescribed amendment as intended

Details of editorial change

Schedule 1 to the *Private Health Insurance (Medical Devices and Human Tissue Products) Amendment (No. 2) Rules 2024* provides as follows:

Schedule 1—Amendments

Private Health Insurance (Medical Devices and Human Tissue Products) (No. 1) Rules 2024

1 Schedule 1

Repeal the Schedule, substitute: the updated Schedule 1 – Listed medical devices and human tissue products.

The title to be amended reads “*Private Health Insurance (Medical Devices and Human Tissue Products) (No. 1) Rules 2024*” rather than the correct title of “*Private Health Insurance (Medical Devices and Human Tissue Products) Rules (No. 1) 2024*”.

This compilation was editorially changed by applying the amendment from Schedule 1 to the *Private Health Insurance (Medical Devices and Human Tissue Products) Amendment (No. 2) Rules 2024* to the *Private Health Insurance (Medical Devices and Human Tissue Products) Rules (No. 1) 2024* to give effect to the misdescribed amendment as intended.

Great Barrier Reef Marine Park Regulations 2019, Compilation No. 11, Registration Date: 28 October 2024 [F2024C00994]

Subparagraph 15(3)(b)(iv)

Kind of editorial change

Change to punctuation

Details of editorial change

Schedule 1 item 19 of the *Great Barrier Reef Marine Park Amendment (Fisheries Reforms) Regulations 2024* instructs to omit a semicolon and substitute a full stop in subparagraph 15(3)(b)(iv).

Subparagraph 15(3)(b)(iv) ends in a full stop despite being followed by paragraph (c).

This compilation was editorially changed to omit the full stop at the end of subparagraph 15(3)(b)(iv) and substitute a semicolon to bring it into line with legislative drafting practice.

Subparagraph 27(1)(b)(ii)

Kind of editorial change

Change to punctuation

Details of editorial change

Schedule 1 item 22 of the *Great Barrier Reef Marine Park Amendment (Fisheries Reforms) Regulations 2024* provides as follows:

22 At the end of subsection 27(1)

Add:

- ; (g) subject to subsection (1A), a commercial fisher must not carry out netting in the net free north area:
 - (i) using a relevant net to take fish for commercial purposes; or
 - (ii) if the fisher possesses, while in the area, a relevant net (or a net that would be a relevant net if used as designed or intended), for taking fish for commercial purposes (unless the net is stowed or secured on a vessel);
- (h) subject to subsection (1A), a commercial fisher must not carry out netting in the net free south area using a relevant net to take fish for commercial purposes.

This amendment results in two semicolons at the end of subparagraph 27(1)(b)(ii).

This compilation was editorially changed to remove the extra semicolon at the end of subparagraph 27(1)(b)(ii) to bring it into line with legislative drafting practice.

Civil Aviation (Buildings Control) Regulations 1988, Compilation No. 4, Registration Date: 24 October 2024 [F2024C00971]

Plan of Melbourne Airport and Essendon Airport showing areas affected by the Civil Aviation (Buildings Control) Regulations at the end of the instrument

Kind of editorial change

Updates to references to a person, body or other entity, or an office, position, place, document or thing

Details of editorial change

Schedule 1 items 11–16 of the *Airports Legislation Amendment (Essendon Fields Airport) Regulations 2017* updated references from “Essendon Airport” to “Essendon Fields Airport”.

The Plan of Melbourne Airport and Essendon Airport showing areas affected by the Civil Aviation (Buildings Control) Regulations at the end of the instrument does not form part of the instrument.

This compilation was editorially changed to omit the words “ESSENDON AIRPORT” (wherever occurring) and substitute “ESSENDON FIELDS AIRPORT” to update the references to the airport site.

National Health (Listing of Pharmaceutical Benefits) Instrument 2024 (PB 26 of 2024), Compilation No. 5, Registration Date: 24 October 2024 [F2024C00967]

Kind of editorial change

Give effect to the misdescribed amendments as intended

Details of editorial change

In the *National Health (Listing of Pharmaceutical Benefits) Amendment (Maximum Dispensed Quantities September Update) Instrument 2024* (PB 85 of 2024), the heading to Schedule 1 does not appear. Schedule 1 also does not specify which instrument is to be amended.

This compilation was editorially changed by applying the amendments from Schedule 1 of the *National Health (Listing of Pharmaceutical Benefits) Amendment (Maximum Dispensed Quantities September Update) Instrument 2024* (PB 85 of 2024) to the *National Health (Listing of Pharmaceutical Benefits) Instrument 2024* (PB 26 of 2024) to give effect to the misdescribed amendments as intended.

Kind of editorial change

Give effect to the misdescribed amendments as intended

Details of editorial change

Schedule 1 items 39, 97, 105, 107, 109, 111, 114, 116, 143, 178, 214, 223, 237, 239, 259, 262, 264, 346, 348, 350, 385, 387, 389, 391, 406, 438 and 443 of the *National Health (Listing of Pharmaceutical Benefits) Amendment (Maximum Dispensed Quantities September Update) Instrument 2024* (PB 85 of 2024) instruct to omit or substitute the entry for a drug or form or brand of a drug. However, multiple entries of these drugs or forms or brands of drugs exist.

This compilation was editorially changed to apply the amendments to the entries listed in the table below to give effect to the misdescribed amendments as intended.

Amending provision	Principal provision Schedule 1, Part 1
39	Amoxicillin with clavulanic acid in the form Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) [<i>Brand: AlphaClav Duo Forte</i>]
97	Budesonide with formoterol in the form Pressurised inhalation containing budesonide 50 micrograms with formoterol fumarate dihydrate 3 micrograms per dose, 120 doses
105	Candesartan in the form Tablet containing candesartan cilexetil 4 mg [<i>Brand: Blooms the Chemist Candesartan</i>]
107	Candesartan in the form Tablet containing candesartan cilexetil 8 mg [<i>Brand: Blooms the Chemist Candesartan</i>]
109	Candesartan in the form Tablet containing candesartan cilexetil 16 mg [<i>Brand: Blooms the Chemist Candesartan</i>]
111	Candesartan in the form Tablet containing candesartan cilexetil 32 mg [<i>Brand: Blooms the Chemist Candesartan</i>]
114	Candesartan with hydrochlorothiazide in the form Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 12.5 mg [<i>Brand: Blooms the Chemist Candesartan HCTZ 32/12.5</i>]
116	Candesartan with hydrochlorothiazide in the form Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 25 mg [<i>Brand: Blooms the Chemist Candesartan HCTZ 32/25</i>]
143	Clopidogrel in the form Tablet 75 mg (as besilate) [<i>Brand: BTC Clopidogrel</i>]
178	Fenofibrate in the form Tablet 145 mg [<i>Brand: Blooms the Chemist Fenofibrate</i>]
214	Glimepiride in the form Tablet 1 mg [<i>Brand: Amaryl</i>]
223	Granisetron in the form Concentrated injection 3 mg (as hydrochloride) in 3 mL [<i>Brand: Granisetron Kabi</i>]
237(a)	Irbesartan in the form Tablet 75 mg [<i>Brand: Avapro</i>]
237(b)	Irbesartan in the form Tablet 75 mg [<i>Brand: Blooms the Chemist Irbesartan</i>]
239	Irbesartan in the form Tablet 150 mg [<i>Brand: Blooms the Chemist Irbesartan</i>]
259	Leflunomide in the form Tablet 10 mg [<i>Brand: Arabloc</i>]
262	Lercanidipine in the form Tablet containing lercanidipine hydrochloride 10 mg [<i>Brand: BTC Lercanidipine</i>]
264	Lercanidipine in the form Tablet containing lercanidipine hydrochloride 20 mg [<i>Brand: BTC Lercanidipine</i>]
346	Perindopril in the form Tablet containing perindopril erbumine 2 mg [<i>Brand: BTC Perindopril</i>]
348	Perindopril in the form Tablet containing perindopril erbumine 4 mg [<i>Brand: BTC Perindopril</i>]
350	Perindopril in the form Tablet containing perindopril erbumine 8 mg [<i>Brand: BTC Perindopril</i>]
385	Rosuvastatin in the form Tablet 5 mg (as calcium) [<i>Brand: Blooms the Chemist Rosuvastatin</i>]
387	Rosuvastatin in the form Tablet 10 mg (as calcium) [<i>Brand: Blooms the Chemist Rosuvastatin</i>]
389	Rosuvastatin in the form Tablet 20 mg (as calcium) [<i>Brand: Blooms the Chemist Rosuvastatin</i>]

Amending provision	Principal provision Schedule 1, Part 1
391	Rosuvastatin in the form Tablet 40 mg (as calcium) [<i>Brand: Blooms the Chemist Rosuvastatin</i>]
406	Second entry for Sofosbuvir with velpatasvir and voxilaprevir in the form Tablet containing 400 mg sofosbuvir with 100 mg velpatasvir and 100 mg voxilaprevir
438	Trastuzumab
443	Triglycerides, long chain with glucose polymer in the form Oral liquid 250 mL, 18 (ProZero)

Veterans' Entitlements Regulations 1986, Compilation No. 18, Registration Date: 21 October 2024 [F2024C00926]

Table 1 of Schedule 2 (table item 1, column 2)

Kind of editorial change

Change to punctuation

Details of editorial change

This compilation was editorially changed to insert a closing bracket after “(other than subparagraph (b)(iii)” in Table 1 of Schedule 2 (table item 1, column 2) to correct the punctuation.

Reserve Bank Act 1959, Compilation No. 31, Registration Date: 18 October 2024 [C2024C00696]

Subsection 5(1)

Kind of editorial change

Reordering of definitions

Details of editorial change

This compilation was editorially changed to move the definition of *payment system* in subsection 5(1) to the correct alphabetical position.

Healthcare Identifiers Act 2010, Compilation No. 19, Registration Date: 17 October 2024 [C2024C00693]

Section 5

Kind of editorial change

Reordering of definitions

Details of editorial change

This compilation was editorially changed to move the definitions of *registered portal operator* and *registered repository operator* in section 5 to the correct alphabetical positions.

Health and Other Services (Compensation) Act 1995, Compilation No. 23, Registration Date: 14 October 2024 [C2024C00653]

Subsection 3(1)

Kind of editorial change

Reordering of definitions

Details of editorial change

This compilation was editorially changed to move the definition of *amount of compensation* in subsection 3(1) to the correct alphabetical position.

Interactive Gambling Act 2001, Compilation No. 24, Registration Date: 14 October 2024 [C2024C00646]

Subsection 61JI(6) (second occurring)

Kind of editorial change

Numbering or renumbering of provisions

Details of editorial change

Section 61JI contains two subsection (6)s.

This compilation was editorially changed by renumbering the second occurring subsection 61JI(6) as subsection 61JI(7).

Liquid Fuel Emergency Act 1984, Compilation No. 16, Registration Date: 14 October 2024 [C2024C00640]

Subsection 10(2) (second occurring)

Kind of editorial change

Numbering or renumbering of provisions

Details of editorial change

Section 10 contains two subsection (2)s.

This compilation was editorially changed by renumbering the second occurring subsection 10(2) as subsection 10(5).

Migration Act 1958, Compilation No. 162, Registration Date: 14 October 2024 [C2024C00442]

Subparagraph 66(2)(d)(iv)

Kind of editorial change

Removal of redundant text

Details of editorial change

Schedule 2 items 20 and 21 of the *Administrative Review Tribunal (Consequential and Transitional Provisions No. 1) Act 2024* provide as follows:

20 Subparagraph 66(2)(d)(iv)

Omit “made;”, substitute “made.”.

21 Paragraphs 66(2)(e) and (f)

Repeal the paragraphs.

Subparagraph 66(2)(d)(iv) ends with “made. and” despite being the last subparagraph of subsection 66(2).

This compilation was editorially changed to omit “and” at the end of subparagraph 66(2)(d)(iv) to remove the redundant text.

Paragraph 197D(6)(a)

Kind of editorial change

Removal of redundant text

Details of editorial change

Schedule 2 item 53 of the *Administrative Review Tribunal (Consequential and Transitional Provisions No. 1) Act 2024* instructs to omit “a valid application for review having been” and substitute “an application for review having been properly made” in paragraph 197D(6)(a).

This amendment results in two consecutive occurrences of the word “made”.

This compilation was editorially changed to omit “made made” and substitute “made” in paragraph 197D(6)(a) to remove the redundant text.

Subsection 474(2) (definition of *privative clause decision*)

Kind of editorial change

Give effect to the misdescribed amendment as intended

Details of editorial change

Schedule 2 item 229 of the *Administrative Review Tribunal (Consequential and Transitional Provisions No. 1) Act 2024* instructs to insert “, (4A)” after “subsection 474(4)” in the definition of *privative clause decision* in subsection 474(2).

The text “subsection 474(4)” does not appear in the definition of *privative clause decision* in subsection 474(2). However, the text “subsection (4)” does appear.

This compilation was editorially changed to insert “, (4A)” after “subsection (4)” in the definition of *privative clause decision* in subsection 474(2) to give effect to the misdescribed amendment as intended.

Nuclear Non-Proliferation (Safeguards) Act 1987, Compilation No. 21, Registration Date: 14 October 2024 [C2024C00562]

Subsection 41(3)

Kind of editorial change

Reordering of definitions

Details of editorial change

This compilation was editorially changed to move the definition of *relevant permit* in subsection 41(3) to the correct alphabetical position.

Paid Parental Leave Act 2010, Compilation No. 45, Registration Date: 14 October 2024 [C2024C00582]

Subsection 224(1A)

Kind of editorial change

Correct a typographical error

Details of editorial change

Schedule 3 item 118 of the *Administrative Review Tribunal (Consequential and Transitional Provisions No. 1) Act 2024* provides as follows:

118 After subsection 224(1)

Insert:

- (1A) If a guidance and appeals panel application is taken to have been made because the ART’s decision on review of an AAT reviewable employer decision is referred to the guidance and appeals panel, review of the decision to which that application relates is also an *ART review*.

Subsection 224(1A) refers to “AAT reviewable employer decision” rather than “ART reviewable employer decision”.

This compilation was editorially changed to omit “AAT reviewable employer decision” and substitute “ART reviewable employer decision” in subsection 224(1A) to correct the typographical error.

Seafarers Rehabilitation and Compensation Act 1992, Compilation No. 33, Registration Date: 14 October 2024 [C2024C00436]

Subsection 89(2)

Kind of editorial change

Update to a reference of a law or a provision

Details of editorial change

Schedule 6 item 63 of the *Administrative Review Tribunal (Consequential and Transitional Provisions No. 2) Act 2024* instructs to omit “18C of the AAT Act” and substitute “57 of the AAT Act” in subsection 89(2).

This compilation was editorially changed to update a reference from “AAT Act” to “ART Act” in subsection 89(2).

List of Exempt Native Specimens Instrument 2001, Compilation No. 426, Registration Date: 4 October 2024 [F2024C00854]

Schedule 1, entry for Queensland Gulf of Carpentaria Developmental Fin Fish Trawl Fishery

Kind of editorial change

Give effect to the misdescribed amendment as intended

Details of editorial change

Schedule 1 of the *Amendment of List of Exempt Native Specimens – Queensland Gulf of Carpentaria Developmental Fin Fish Trawl Fishery, September 2024* provides as follows:

Under the heading Freshwater and Marine Animals delete from the list the following items and any associated notations:

Taxon/Item	Common Name	Notation
Specimen that are, or are derived from, fish or invertebrates taken in the Queensland Gulf of Carpentaria Developmental Fin Fish Trawl Fishery under the management regime in force under the <i>Queensland Fisheries Act 1994</i> , Fisheries (General) Regulation 2019 and Queensland Gulf of Carpentaria Developmental Fin Fish Trawl Fishery developmental fishing permits, but not including: a. specimens that belong to taxa listed under section 209 of the EPBC Act (Australia’s list of Migratory Species), or b. specimens that belong to taxa	Queensland Gulf of Carpentaria Developmental Fin Fish Trawl Fishery	<ul style="list-style-type: none">• The specimen, or the fish or invertebrate from which it is derived, was taken lawfully;• The specimens are covered by the declaration of an approved wildlife trade operation under section 303FN of the EPBC Act in relation to the fishery.

Taxon/Item	Common Name	Notation
<p>listed under section 248 of the EPBC Act (Australia's list of Marine Species), or</p> <p>c. specimens that belong to eligible listed threatened species, as defined under section 303BC of the EPBC Act, or</p> <p>d. specimens that belong to taxa listed under section 303CA of the EPBC Act (Australia's CITES List).</p>		

The text contained in the Taxon/Item and Notation columns of the Schedule 1 entry for the Queensland Gulf of Carpentaria Developmental Fin Fish Trawl Fishery does not exactly match the text to be omitted as outlined in Schedule 1 of the *Amendment of List of Exempt Native Specimens – Queensland Gulf of Carpentaria Developmental Fin Fish Trawl Fishery, September 2024*.

This compilation was editorially changed to omit the Schedule 1 entry for the Queensland Gulf of Carpentaria Developmental Fin Fish Trawl Fishery and give effect to the misdescribed amendment as intended.

Road Vehicle Standards (Information on the Register of Approved Vehicles) Determination 2021, Compilation No. 1, Registration Date: 25 September 2024 [F2024C00819]

Subsection 5(1)

Kind of editorial change

Reordering of definitions

Details of editorial change

This compilation was editorially changed to move the definitions of *older vehicle* and *Regulation 85* in subsection 5(1) to the correct alphabetical positions.

National Redress Scheme for Institutional Child Sexual Abuse Declaration 2018, Compilation No. 71, Registration Date: 19 September 2024 [F2024C00809]

Schedule 1 (table item 423)

Kind of editorial change

Give effect to the misdescribed amendment as intended

Details of editorial change

Schedule 1 item 10 of the *National Redress Scheme for Institutional Child Sexual Abuse Amendment (2024 Measures No. 3) Declaration 2024* provides as follows:

10 Schedule 1 (table item 423, column 2)

After the words “Morialta Trust” insert the word “Inc”.

Omit (a) to (d).

The words “Morialta Trust” and paragraphs (a) to (d) do not appear in the column headed “**Column 2**” of table item 423 of Schedule 1. However, the words “Morialta Trust” and paragraphs (a) to (d) do appear in the column headed “**Column 1**” of table item 423 of Schedule 1.

This compilation was editorially changed to insert the word “Inc” after the words “Morialta Trust” and to omit paragraphs (a) to (d) in the column headed “**Column 1**” of table item 423 of Schedule 1 to give effect to the misdescribed amendment as intended.

National Health (Listing of Pharmaceutical Benefits) Instrument 2024 (PB 26 of 2024), Compilation No. 4, Registration Date: 18 September 2024 [F2024C00807]

Kind of editorial change

Give effect to the misdescribed amendments as intended

Details of editorial change

Schedule 1 items 4–6, 13, 14, 25, 27–29, 52–56, 58–60, 90, 96, 113, 119, 120, 128, 130, 131, 139–142, 160 and 163–165 of the *National Health (Listing of Pharmaceutical Benefits) Amendment (August Update) Instrument 2024* (PB 76 of 2024) instruct to substitute the entry for a drug or form of a drug. However, multiple entries of these drugs or forms of drugs exist.

This compilation was editorially changed to substitute all entries for the drug or form of the drug listed in the table below to give effect to the misdescribed amendments as intended.

Schedule 1, Part 1
Adalimumab in the form Injection 20 mg in 0.2 mL pre-filled syringe
Adalimumab in the form Injection 20 mg in 0.4 mL pre-filled syringe
Adalimumab in the form Injection 40 mg in 0.4 mL pre-filled pen
Adalimumab in the form Injection 40 mg in 0.8 mL pre-filled pen
Adalimumab in the form Injection 40 mg in 0.8 mL pre-filled syringe
Amoxicillin in the form Powder for paediatric oral drops 100 mg (as trihydrate) per mL, 20 mL
Arsenic
Atezolizumab
Avelumab
Benralizumab
Benzatropine in the form Injection containing benzatropine mesilate 2 mg in 2 mL
Benzylpenicillin in the form Powder for injection 3 g (as sodium)
Betaxolol
Bimatoprost
Brentuximab vedotin
Brimonidine
Brinzolamide
Codeine with paracetamol

Schedule 1, Part 1

Durvalumab

Larotrectinib

Methotrexate

Metoclopramide

Nivolumab

Oxycodone in the form Capsule containing oxycodone hydrochloride 5 mg

Oxycodone in the form Capsule containing oxycodone hydrochloride 10 mg

Quetiapine in the form Tablet (modified release) 50 mg (as fumarate)

Quetiapine in the form Tablet (modified release) 200 mg (as fumarate)

Quetiapine in the form Tablet (modified release) 300 mg (as fumarate)

Quetiapine in the form Tablet (modified release) 400 mg (as fumarate)

Tenofovir

Timolol

Valganciclovir

Zoledronic acid in the form Injection concentrate for I.V. infusion 4 mg (as monohydrate) in 5 mL

Kind of editorial change

Give effect to the misdescribed amendments as intended

Details of editorial change

Schedule 1 items 70–80, 84, 85, 89 and 146–153 of the *National Health (Listing of Pharmaceutical Benefits) Amendment (August Update) Instrument 2024* (PB 76 of 2024) instruct to amend or omit the entry, the location of which is specified by reference to the drug's form, brand, maximum quantity and number of repeats. However, there are multiple entries in the locations specified.

This compilation was editorially changed to apply the amendments to the entries listed in the table below to give effect to the misdescribed amendments as intended.

Amending provision	Principal provision Schedule 1, Part 1
70(a)	First entry for Cefalexin in the form Capsule 250 mg (as monohydrate) [<i>Brand: APO-Cephalexin; Maximum Quantity: 20; Number of Repeats: 0</i>]
70(b)	Second entry for Cefalexin in the form Capsule 250 mg (as monohydrate) [<i>Brand: APO-Cephalexin; Maximum Quantity: 20; Number of Repeats: 0</i>]
71(a)	First entry for Cefalexin in the form Capsule 250 mg (as monohydrate) [<i>Brand: Ibilex 250; Maximum Quantity: 20; Number of Repeats: 0</i>]
71(b)	Second entry for Cefalexin in the form Capsule 250 mg (as monohydrate) [<i>Brand: Ibilex 250; Maximum Quantity: 20; Number of Repeats: 0</i>]
72(a)	First entry for Cefalexin in the form Capsule 250 mg (as monohydrate) [<i>Brand: Keflex; Maximum Quantity: 20; Number of Repeats: 0</i>]
72(b)	Second entry for Cefalexin in the form Capsule 250 mg (as monohydrate) [<i>Brand: Keflex; Maximum Quantity: 20; Number of Repeats: 0</i>]
73(a)	First entry for Cefalexin in the form Capsule 500 mg (as monohydrate) [<i>Brand: APO-Cephalexin; Maximum Quantity: 20; Number of Repeats: 0</i>]
73(b)	Second entry for Cefalexin in the form Capsule 500 mg (as monohydrate) [<i>Brand: APO-Cephalexin; Maximum Quantity: 20; Number of Repeats: 0</i>]

Amending provision	Principal provision Schedule 1, Part 1
74(a)	First entry for Cefalexin in the form Capsule 500 mg (as monohydrate) [<i>Brand: Blooms The Chemist Cefalexin; Maximum Quantity: 20; Number of Repeats: 0</i>]
74(b)	Second entry for Cefalexin in the form Capsule 500 mg (as monohydrate) [<i>Brand: Blooms The Chemist Cefalexin; Maximum Quantity: 20; Number of Repeats: 0</i>]
75(a)	First entry for Cefalexin in the form Capsule 500 mg (as monohydrate) [<i>Brand: Cefalexin Sandoz; Maximum Quantity: 20; Number of Repeats: 0</i>]
75(b)	Second entry for Cefalexin in the form Capsule 500 mg (as monohydrate) [<i>Brand: Cefalexin Sandoz; Maximum Quantity: 20; Number of Repeats: 0</i>]
76(a)	First entry for Cefalexin in the form Capsule 500 mg (as monohydrate) [<i>Brand: Cephalax 500; Maximum Quantity: 20; Number of Repeats: 0</i>]
76(b)	Second entry for Cefalexin in the form Capsule 500 mg (as monohydrate) [<i>Brand: Cephalax 500; Maximum Quantity: 20; Number of Repeats: 0</i>]
77(a)	First entry for Cefalexin in the form Capsule 500 mg (as monohydrate) [<i>Brand: Cephalaxin generichealth; Maximum Quantity: 20; Number of Repeats: 0</i>]
77(b)	Second entry for Cefalexin in the form Capsule 500 mg (as monohydrate) [<i>Brand: Cephalaxin generichealth; Maximum Quantity: 20; Number of Repeats: 0</i>]
78(a)	First entry for Cefalexin in the form Capsule 500 mg (as monohydrate) [<i>Brand: Ibilex 500; Maximum Quantity: 20; Number of Repeats: 0</i>]
78(b)	Second entry for Cefalexin in the form Capsule 500 mg (as monohydrate) [<i>Brand: Ibilex 500; Maximum Quantity: 20; Number of Repeats: 0</i>]
79(a)	First entry for Cefalexin in the form Capsule 500 mg (as monohydrate) [<i>Brand: Keflex; Maximum Quantity: 20; Number of Repeats: 0</i>]
79(b)	Second entry for Cefalexin in the form Capsule 500 mg (as monohydrate) [<i>Brand: Keflex; Maximum Quantity: 20; Number of Repeats: 0</i>]
80(a)	First entry for Cefalexin in the form Capsule 500 mg (as monohydrate) [<i>Brand: NOUMED CEFALEXIN; Maximum Quantity: 20; Number of Repeats: 0</i>]
80(b)	Second entry for Cefalexin in the form Capsule 500 mg (as monohydrate) [<i>Brand: NOUMED CEFALEXIN; Maximum Quantity: 20; Number of Repeats: 0</i>]
84(a)	First entry for Cetuximab in the form Solution for I.V. infusion 100 mg in 20 mL
84(b)	First entry for Cetuximab in the form Solution for I.V. infusion 100 mg in 20 mL
84(c)	Second to fifth entries for Cetuximab in the form Solution for I.V. infusion 100 mg in 20 mL
85(a)	First entry for Cetuximab in the form Solution for I.V. infusion 500 mg in 100 mL
85(b)	First entry for Cetuximab in the form Solution for I.V. infusion 500 mg in 100 mL
85(c)	Second to fifth entries for Cetuximab in the form Solution for I.V. infusion 500 mg in 100 mL
89(a)	First entry for Codeine in the form Tablet containing codeine phosphate hemihydrate 30 mg [<i>Maximum Quantity: 10; Number of Repeats: 0</i>]
89(b)	Second entry for Codeine in the form Tablet containing codeine phosphate hemihydrate 30 mg [<i>Maximum Quantity: 10; Number of Repeats: 0</i>]
146(a)	First entry for Roxithromycin in the form Tablet 150 mg [<i>Brand: APO-Roxithromycin; Maximum Quantity: 10; Number of Repeats: 0</i>]
146(b)	Second entry for Roxithromycin in the form Tablet 150 mg [<i>Brand: APO-Roxithromycin; Maximum Quantity: 10; Number of Repeats: 0</i>]
147(a)	First entry for Roxithromycin in the form Tablet 150 mg [<i>Brand: APX-Roxithromycin; Maximum Quantity: 10; Number of Repeats: 0</i>]
147(b)	Second entry for Roxithromycin in the form Tablet 150 mg [<i>Brand: APX-Roxithromycin; Maximum Quantity: 10; Number of Repeats: 0</i>]

Amending provision	Principal provision Schedule 1, Part 1
148(a)	First entry for Roxithromycin in the form Tablet 150 mg [<i>Brand: Roxar 150; Maximum Quantity: 10; Number of Repeats: 0</i>]
148(b)	Second entry for Roxithromycin in the form Tablet 150 mg [<i>Brand: Roxar 150; Maximum Quantity: 10; Number of Repeats: 0</i>]
149(a)	First entry for Roxithromycin in the form Tablet 150 mg [<i>Brand: Roxithromycin Sandoz; Maximum Quantity: 10; Number of Repeats: 0</i>]
149(b)	Second entry for Roxithromycin in the form Tablet 150 mg [<i>Brand: Roxithromycin Sandoz; Maximum Quantity: 10; Number of Repeats: 0</i>]
150(a)	First entry for Roxithromycin in the form Tablet 300 mg [<i>Brand: APO-Roxithromycin; Maximum Quantity: 5; Number of Repeats: 0</i>]
150(b)	Second entry for Roxithromycin in the form Tablet 300 mg [<i>Brand: APO-Roxithromycin; Maximum Quantity: 5; Number of Repeats: 0</i>]
151(a)	First entry for Roxithromycin in the form Tablet 300 mg [<i>Brand: APX-Roxithromycin; Maximum Quantity: 5; Number of Repeats: 0</i>]
151(b)	Second entry for Roxithromycin in the form Tablet 300 mg [<i>Brand: APX-Roxithromycin; Maximum Quantity: 5; Number of Repeats: 0</i>]
152(a)	First entry for Roxithromycin in the form Tablet 300 mg [<i>Brand: Roxar 300; Maximum Quantity: 5; Number of Repeats: 0</i>]
152(b)	Second entry for Roxithromycin in the form Tablet 300 mg [<i>Brand: Roxar 300; Maximum Quantity: 5; Number of Repeats: 0</i>]
153(a)	First entry for Roxithromycin in the form Tablet 300 mg [<i>Brand: Roxithromycin Sandoz; Maximum Quantity: 5; Number of Repeats: 0</i>]
153(b)	Second entry for Roxithromycin in the form Tablet 300 mg [<i>Brand: Roxithromycin Sandoz; Maximum Quantity: 5; Number of Repeats: 0</i>]

Work Health and Safety Regulations 2011, Compilation No. 26, Registration Date: 7 September 2024 [F2024C00788]

Regulations 529A, 529B and 529C

Kind of editorial change

Give effect to the misdescribed amendment as intended

Details of editorial change

Schedule 3 item 6 of the *Work Health and Safety Amendment (Penalties and Engineered Stone and Crystalline Silica Substances) Regulations 2024* instructs to repeal regulations 529A to 529C and substitute regulations 529A to 529C and 529CA to 529CE.

Regulation 592C does not appear. However, regulation 529C does appear.

This compilation was editorially changed to repeal regulations 529A to 529C and substitute regulations 529A to 529C and 529CA to 529CE to give effect to the misdescribed amendment as intended.

Defence Trade Controls Act 2012, Compilation No. 8, Registration Date: 6 September 2024 [C2024C00355]

Subparagraph 5C(1C)(a)(ii)

Kind of editorial change

Change to punctuation

Details of editorial change

Schedule 1 item 5 of the *Defence Trade Controls Amendment Act 2024* instructs to insert sections 5AA, 5B and 5C after section 5A.

Subparagraph 5C(1C)(a)(ii) reads as follows:

- (ii) a body corporate incorporated by or under a law of a foreign country that is specified in an instrument under that subsection; or of part of such a country;

This compilation was editorially changed to omit the semicolon after the word “subsection” and substitute a comma in subparagraph 5C(1C)(a)(ii) to correct the punctuation.

National Greenhouse and Energy Reporting (Measurement) Determination 2008, Compilation No. 17, Registration Date: 3 September 2024 [F2024C00775]

Section 2.67

Kind of editorial change

Give effect to the misdescribed amendment as intended

Details of editorial change

Schedule 1 item 4 of the *National Greenhouse and Energy Reporting (Measurement) Amendment (2024 Update) Determination 2024* provides as follows:

4 Section 2.67 (notation)

At the end of the section, insert:

Note: The application of this section is subject to section 2.67B.

There is no notation in section 2.67.

This compilation was editorially changed to insert the note at the end of section 2.67 to give effect to the misdescribed amendment as intended.

Subsection 3.46A(3)

Kind of editorial change

Give effect to the misdescribed amendment as intended

Details of editorial change

Schedule 1 item 11 of the *National Greenhouse and Energy Reporting (Measurement) Amendment (2024 Update) Determination 2024* provides as follows:

11 Subsection 3.46A(3)

Omit “process vents, systems upsets and accidents”, substitute “system upsets, accidents and deliberate releases from process vents”.

The text “process vents, systems upsets and accidents” does not appear in subsection 3.46A(3). However, the text “process vents, system upsets and accidents” does appear.

This compilation was editorially changed to omit “process vents, system upsets and accidents” from subsection 3.46A(3) and substitute “system upsets, accidents and deliberate releases from process vents” to give effect to the misdescribed amendment as intended.

Sections 3.85A, 3.85K and 3.85M

Kind of editorial change

Give effect to the misdescribed amendment as intended and change to capitalisation

Details of editorial change

Schedule 1 item 15 of the *National Greenhouse and Energy Reporting (Measurement) Amendment (2024 Update) Determination 2024* provides as follows:

15 Sections 3.85A, 3.85B, 3.85K, 3.85L, 3.85M, 3.85N

Omit every occurrence of “Method 1”, substitute “Method 2”.

The text “Method 1” does not appear in sections 3.85A, 3.85K and 3.85M. However, the text “method 1” does appear.

This compilation was editorially changed to omit “method 1” from sections 3.85A, 3.85K and 3.85M and substitute “method 2” to give effect to the misdescribed amendment as intended and to correct the capitalisation.

Subsections 5.4(3) and 5.15(4) (definition of CEA)

Kind of editorial change

Give effect to the misdescribed amendment as intended and change to typeface

Details of editorial change

Schedule 1 item 25 of the *National Greenhouse and Energy Reporting (Measurement) Amendment (2024 Update) Determination 2024* provides as follows:

25 Subsections 5.4(3) and 5.15(4) (definition of CEA)

Omit “CEA”, substitute “CEL”.

The word “CEA” does not appear in the definition of *CEA* in subsections 5.4(3) and 5.15(4). However, the word “*CEA*” does appear.

This compilation was editorially changed to omit “*CEA*” from the definition of *CEA* in subsections 5.4(3) and 5.15(4) and substitute “*CEL*” to give effect to the misdescribed amendment as intended and bring it into line with legislative drafting practice.

Part 2 of Schedule 4 (Sources 2T and 2U tables)

Kind of editorial change

Removal of redundant text

Details of editorial change

Schedule 1 items 38 and 39 of the *National Greenhouse and Energy Reporting (Measurement) Amendment (2024 Update) Determination 2024* provide as follows:

38 Schedule 4, Part 2, under Source 2T—Onshore natural gas production—flaring (after Table item 2)

Insert:

Item	Method	Matters to be identified
3	Method 2B for the source, as set out in subsection 3.87B(1)	(a) the tonnes of flared gas (b) the tonnes and gigajoules of methane within the flared gas, calculated through a mass balance
4	Method 2B for the source, as set out in subsection 3.87B(2)	(a) the tonnes of flared crude oil and liquids (hydrocarbon component) within the flared gas, calculated through a mass balance

39 Schedule 4, Part 2, under Source 2U—Offshore natural gas production—flaring (after Table item 2)

Insert:

Item	Method	Matters to be identified
3	Method 2B for the source, as set out in subsection 3.87B(1)	(a) the tonnes of flared gas (b) the tonnes and gigajoules of methane within the flared gas, calculated through a mass balance
4	Method 2B for the source, as set out in subsection 3.87B(2)	(a) the tonnes of flared crude oil and liquids (hydrocarbon component) within the flared gas, calculated through a mass balance

These amendments result in two occurrences of the table column headings in the tables.

This compilation was editorially changed to omit the second occurrence of the table column headings from the Sources 2T and 2U tables in Part 2 of Schedule 4 to remove the redundant text.

Fair Work Act 2009, Compilation No. 62, Registration Date: 26 August 2024 [C2024C00349]

Subsection 620(1G)

Kind of editorial change

Give effect to the misdescribed amendment as intended

Details of editorial change

Schedule 1 item 245A of the *Fair Work Legislation Amendment (Closing Loopholes No. 2) Act 2024* provides as follows:

245A Before subsection 620(2)

Additional requirement relating to the constitution of an Expert Panel for deferral or suspension of road transport contractual chain orders

- (1G) If an Expert Panel is constituted under subsection (1E) for a purpose referred to in paragraph 617(10B)(dc), (dd), (de) or (df) in relation to a road transport contractual chain order (which deal with deferral and suspension), a majority of the members of the Expert Panel must not be members of the Expert Panel that made the road transport chain order concerned.

The instruction to insert the subsection is missing.

This compilation was editorially changed to insert subsection 620(1G) before subsection 620(2) to give effect to the misdescribed amendment as intended.

Treatment Principles (No. R52/2013), Compilation No. 32, Registration Date: 23 August 2024 [F2024C00744]

Paragraph 7.3AA.4

Kind of editorial change

Give effect to the misdescribed amendment as intended

Details of editorial change

Schedule 1 item 7 of the *Veterans' Affairs (Treatment Principles) Variation (Sustainability Payments) Determination 2024* provides as follows:

7 Paragraph 7.3AA.4

omit

the person received a *community nursing service* from a particular provider on more than one occasion in the calendar month

substitute

more than one claim for payment was approved in the calendar month for *community nursing services* that the person received from the provider

The words “the person received a *community nursing service* from a particular provider on more than one occasion in the calendar month” do not appear in paragraph 7.3AA.4. However, the words “the person received a *community nursing service* from a particular provider on more than one occasions in the calendar month” do appear.

This compilation was editorially changed to omit “the person received a *community nursing service* from a particular provider on more than one occasions in the calendar month” and substitute “more than one claim for payment was approved in the calendar month for *community nursing services* that the person received from the provider” in paragraph 7.3AA.4 to give effect to the misdescribed amendment as intended.

Paragraph 7.3B.4

Kind of editorial change

Give effect to the misdescribed amendment as intended

Details of editorial change

Schedule 1 item 14 of the *Veterans’ Affairs (Treatment Principles) Variation (Sustainability Payments) Determination 2024* provides as follows:

14 Paragraph 7.3B.4

omit

the person received a service under the program from a particular provider on more than one occasion in the calendar month

substitute

more than one claim for payment was approved in the calendar month for services that the person received from the provider

The words “the person received a service under the program from a particular provider on more than one occasion in the calendar month” do not appear in paragraph 7.3B.4. However, the words “the person received a service under the program from a particular provider on more than one occasions in the calendar month” do appear.

This compilation was editorially changed to omit “the person received a service under the program from a particular provider on more than one occasions in the calendar month” and substitute “more than one claim for payment was approved in the calendar month for services that the person received from the provider” in paragraph 7.3B.4 to give effect to the misdescribed amendment as intended.

**Declaration of an Approved Wildlife Trade Operation –
Commonwealth Western Tuna and Billfish Fishery, November 2023,
Compilation No. 1, Registration Date: 21 August 2024
[F2024C00734]**

Schedule 1 (Condition 6)

Kind of editorial change

Give effect to the misdescribed amendment as intended and change to punctuation

Details of editorial change

The Declaration of an Approved Wildlife Trade Operation – Commonwealth Western Tuna and Billfish Fishery, June 2024 provides as follows:

Delete the words:

Condition 6

The Australian Fisheries Management Authority must:

- a) By 1 November 2024, conduct and publish an updated Ecological Risk Assessment for the Commonwealth Western Tuna and Billfish Fishery using data that best reflects the management arrangements which the fishery currently operates within. The Australian Fisheries Management Authority must ensure the data used to inform the updated Ecological Risk Assessment includes fishing operations data collected since the implementation of electronic monitoring in the fishery
- b) Implement risk mitigation strategies to address any high risks identified in the Ecological Risk Assessment, including for species identified as being at high risk due to a lack of available information. Progress in implementing the risk mitigation strategies should be included in annual reports provided to the Department of Climate Change, Energy, the Environment and Water (as specified at Condition 4 of the wildlife trade operation approval).

and replace with the words:

Condition 6

By 19 February 2025, the Australian Fisheries Management Authority must:

- a) conduct and complete an updated Ecological Risk Assessment for the Commonwealth Western Tuna and Billfish Fishery and provide a copy of the completed assessment to the Department of Climate Change, Energy, the Environment and Water. The Ecological Risk Assessment must use data that reflects current management arrangements in the fishery, including fishing operation data collected since the implementation of electronic monitoring in the fishery.
- b) continue to implement management actions to address and mitigate risks and impacts for species that are identified as high risk, including data collection for species that are assessed as high risk because of missing information.

The text contained in Condition 6 of Schedule 1 does not exactly match the text to be omitted as outlined in the *Declaration of an Approved Wildlife Trade Operation – Commonwealth Western Tuna and Billfish Fishery, June 2024*.

This compilation was editorially changed to apply the amendment to Condition 6 of Schedule 1 to give effect to the misdescribed amendment as intended and to insert a colon after “**Condition 6**” in Schedule 1 to correct the punctuation.

Declaration of an Approved Wildlife Trade Operation – Commonwealth Eastern Tuna and Billfish Fishery, November 2023, Compilation No. 1, Registration Date: 20 August 2024 [F2024C00733]

Schedule 1 (Condition 5)

Kind of editorial change

Give effect to the misdescribed amendment as intended and change to punctuation

Details of editorial change

The Declaration of an Approved Wildlife Trade Operation – Commonwealth Eastern Tuna and Billfish Fishery, June 2024 provides as follows:

Delete the words:

Condition 5

By 30 July 2024, the Australian Fisheries Management Authority must:

- a) publish an updated Ecological Risk Assessment for the Commonwealth Eastern Tuna and Billfish Fishery using data that best reflects the management arrangements which the fishery currently operates within. The Australian Fisheries Management Authority should ensure the data used to inform the updated Ecological Risk Assessment includes fishing operations data collected since the implementation of electronic monitoring in the fishery
- b) continue to implement management actions to address and mitigate risks and impacts for species that are identified as high risk, including data collection for species that are assessed as high risk because of missing information.

and replace with the words:

Condition 5

By 19 February 2025, the Australian Fisheries Management Authority must:

- a) conduct and complete an updated Ecological Risk Assessment for the Commonwealth Eastern Tuna and Billfish Fishery and provide a copy of the completed assessment to the Department of Climate Change, Energy, the Environment and Water. The Ecological Risk Assessment must use data that reflects current management arrangements in the fishery, including fishing operation data collected since the implementation of electronic monitoring in the fishery.
- b) continue to implement management actions to address and mitigate risks and impacts for species that are identified as high risk, including data collection for species that are assessed as high risk because of missing information.

The text “**Condition 5**” does not appear in Schedule 1. However, the text “**Condition 5:**” does appear.

This compilation was editorially changed to apply the amendment to Condition 5 of Schedule 1 to give effect to the misdescribed amendment as intended and to insert a colon after “**Condition 5**” in Schedule 1 to correct the punctuation.

National Health (Listing of Pharmaceutical Benefits) Instrument 2024 (PB 26 of 2024), Compilation No. 3, Registration Date: 14 August 2024 [F2024C00720]

Kind of editorial change

Give effect to the misdescribed amendments as intended

Details of editorial change

Schedule 1 items 25, 26, 32, 43, 67, 68, 81, 90, 384, 394, 407, 419 and 421 of the *National Health (Listing of Pharmaceutical Benefits) Amendment (July Update) Instrument 2024* (PB 68 of 2024) instruct to substitute the entry for a drug or form of a drug. However, multiple entries of these drugs or forms of drugs exist.

This compilation was editorially changed to substitute all entries for the drug or form of the drug listed in the table below to give effect to the misdescribed amendments as intended.

Schedule 1, Part 1
Buprenorphine with naloxone
Calcium in the form Tablet, chewable, 500 mg (as carbonate)
Cetuximab
Dupilumab
Methadone in the form Oral liquid containing methadone hydrochloride 25 mg per 5 mL in 1 L bottle, 1 mL
Methadone in the form Oral liquid containing methadone hydrochloride 25 mg per 5 mL in 200 mL bottle, 1 mL
Pantoprazole in the form Tablet (enteric coated) 40 mg (as sodium sesquihydrate)
Sevelamer in the form Tablet containing sevelamer carbonate 800 mg
Schedule 5
Amoxicillin with clavulanic acid
Desvenlafaxine
Octreotide
Teriparatide
Varenicline

Telecommunications (Statutory Infrastructure Providers—Exempt Real Estate Development Projects and Building Redevelopment Projects) Determination (No.1) 2020, Compilation No. 2, Registration Date: 14 August 2024 [F2024C00721]

Section 4

Kind of editorial change

Removal of redundant text

Details of editorial change

Schedule 1 item 3 of the *Telecommunications (Statutory Infrastructure Providers—Exempt Real Estate Development Projects and Building Redevelopment Projects) Amendment Determination (No. 1) 2024* instructs to repeal subsection 4(2).

Section 4 appears, in part, as follows:

4 Definitions

[...]

- (1) In this Instrument:

Act means the *Telecommunications Act 1997*.

contractual arrangement includes a deed, contract, undertaking or any other form of legally binding arrangement.

project area:

- (a) for a building redevelopment project—has the same meaning as in section 360A of the Act; and
- (b) for a real estate development project—has the same meaning as in subsections 372Q(2) and 372Q(6) of the Act.

Start Date means the day upon which Part 1, Division 2 of Schedule 3 to the *Telecommunications Legislation Amendment (Competition and Consumer) Act 2020* comes into effect.

This compilation was editorially changed to omit “(1)” from section 4 to remove the redundant text and bring it into line with legislative drafting practice.

National Health (Minimum Stockholding) Determination 2023 (PB 65 of 2023), Compilation No. 11, Registration Date: 12 August 2024 [F2024C00705]

Schedule 1

Kind of editorial change

Give effect to the misdescribed amendment as intended

Details of editorial change

Schedule 1 item 1 of the *National Health (Minimum Stockholding) Amendment Determination (No. 7) 2024* (PB 83 of 2024) provides as follows:

1 Schedule 1 (table)

Before:

Acamprosate	Tablet (enteric coated) containing acamprosate calcium 333 mg	Oral	Acamprosate Viatris	after 30 July 2024—4 months stock by reference to usual demand of both Acamprosate Viatris and Acamprosate Mylan added together.
-------------	---	------	---------------------	--

insert:

Abacavir with lamivudine	Tablet containing abacavir 600 mg (as sulfate) with lamivudine 300 mg	Oral	ABACAVIR/LAMI VUDINE 600/300 SUN	between 1 August 2024 and 30 September 2024—0 months stock by reference to usual demand
--------------------------	---	------	----------------------------------	---

The text contained in the column headed “**Column 5 Applicable quantity**” for the entry of Acamprosate does not exactly match the text as outlined in Schedule 1 item 1 of the *National Health (Minimum Stockholding) Amendment Determination (No. 7) 2024* (PB 83 of 2024).

This compilation was editorially changed to insert the entry for Abacavir with lamivudine before the entry for Acamprosate in Schedule 1 to give effect to the misdescribed amendment as intended.

Industrial Chemicals Charges (Customs) Regulations 2020, Compilation No. 3, Registration Date: 26 July 2024 [F2024C00665]

Section 7

Kind of editorial change

Removal of redundant text

Details of editorial change

Section 7 appears as follows:

7 Application of amendments made by the *Industrial Chemicals Charges (Customs) Amendment Regulations 2023*

- (1) The amendments made by Part 1 of Schedule 1 to the *Industrial Chemicals Charges (Customs) Amendment Regulations 2023* apply in relation to the registration of a person for a registration year beginning on 1 September 2023 and later registration years.

This compilation was editorially changed to omit “(1)” from section 7 to remove the redundant text and bring it into line with legislative drafting practice.

Corporations Act 2001, Compilation No. 134, Registration Date: 25 July 2024 [C2024C00307]

Subparagraph 953B(1)(b)(i)

Kind of editorial change

Give effect to the misdescribed amendment as intended

Details of editorial change

Schedule 1 item 73 of the *Treasury Laws Amendment (Delivering Better Financial Outcomes and Other Measures) Act 2024* provides as follows:

73 Subparagraph 953B(1)(b)(i)

After “disclosure document or statement”, insert “(other than website disclosure information)”.

The words “disclosure document or statement” appear twice in subparagraph 953B(1)(b)(i).

This compilation was editorially changed to insert “(other than website disclosure information)” after “disclosure document or statement” (first occurring) in subparagraph 953B(1)(b)(i) to give effect to the misdescribed amendment as intended.

Customs Act 1901, Compilation No. 182, Registration Date: 23 July 2024 [C2024C00311]

Subsection 71E(3C) (heading)

Kind of editorial change

Give effect to the misdescribed amendment as intended

Details of editorial change

Schedule 1 item 176 of the *Excise and Customs Legislation Amendment (Streamlining Administration) Act 2024* provides as follows:

176 Before subsection 71E(3C)

Certain cargo reports taken to be movement applications

The instruction to insert the subsection heading is missing.

This compilation was editorially changed to insert the subsection heading before subsection 71E(3C) to give effect to the misdescribed amendment as intended.

Subsection 71E(4) (heading)

Kind of editorial change

Give effect to the misdescribed amendment as intended

Details of editorial change

Schedule 1 item 177 of the *Excise and Customs Legislation Amendment (Streamlining Administration) Act 2024* provides as follows:

177 Before subsection 71E(4)

Directions to move goods to a warehouse

The instruction to insert the subsection heading is missing.

This compilation was editorially changed to insert the subsection heading before subsection 71E(4) to give effect to the misdescribed amendment as intended.

National Health (IVF Program) Special Arrangement 2015 (PB 60 of 2015), Compilation No. 18, Registration Date: 22 July 2024 [F2024C00645]

Subsection 17(1)

Kind of editorial change

Give effect to the misdescribed amendment as intended

Details of editorial change

Schedule 1 item 45 of the *National Health Legislation Amendment (Extension of Closing the Gap – PBS Co-payment Program) Instrument 2024* (PB 66 of 2024) provides as follows:

46 Subsection 17(1)

Omit “for a public or a private hospital”.

The words “for a public or a private hospital” do not appear in subsection 17(1). However, the words “for a public hospital or a private hospital” do appear.

This compilation was editorially changed to omit “for a public hospital or a private hospital” from subsection 17(1) to give effect to the misdescribed amendment as intended.

Australian Passports (Application Fees) Determination 2015, Compilation No. 4, Registration Date: 18 July 2024 [F2024C00633]

Subsection 6(3) (note)

Kind of editorial change

Update to a reference of a law or a provision

Details of editorial change

Schedule 1 item 5 of the *Australian Passports (Application Fees) Amendment Determination 2024* instructs to omit and substitute the table in subsection 6(3).

The note to subsection 6(3) refers to “item 3” instead of “item 4” of the newly substituted table.

This compilation was editorially changed to update a reference from “item 3” to “item 4” in the note to subsection 6(3).

Marriage Act 1961, Compilation No. 30, Registration Date: 17 July 2024 [C2024C00265]

Paragraph 39(2A)(a) (second occurring)

Kind of editorial change

Numbering or renumbering of provisions

Details of editorial change

Schedule 3 item 51 of the *Attorney-General’s Portfolio Miscellaneous Measures Act 2024* instructs to insert subsection 39(2A) after subsection 39(2).

The newly inserted subsection 39(2A) contains two paragraph (a)s.

This compilation was editorially changed by renumbering the second occurring paragraph 39(2A)(a) as paragraph 39(2A)(b).

Work Health and Safety Regulations 2011, Compilation No. 25, Registration Date: 15 July 2024 [F2024C00580]

Part 8A.5 of Chapter 8A (heading)

Kind of editorial change

Correct a typographical error

Details of editorial change

Schedule 2 item 3 of the *Work Health and Safety Amendment (Penalties and Engineered Stone and Crystalline Silica Substances) Regulations 2024* instructs to insert Chapter 8A after Chapter 8.

The heading to Part 8A.5 of Chapter 8A is missing an em rule after “**Part 8A.5**”.

This compilation was editorially changed to insert an em rule after “**Part 8A.5**” in the heading to Part 8A.5 of Chapter 8A to bring it into line with legislative drafting practice.

Income Tax Assessment Act 1997, Compilation No. 249, Registration Date: 13 July 2024 [C2024C00280]

Paragraph 275-615(1)(c)

Kind of editorial change

Change to grammar, syntax or the use of conjunctives or disjunctives

Details of editorial change

Paragraph 275-615(1)(c) contains the phrase “at least one the parties”.

This compilation was editorially changed to insert the word “of” between the words “one” and “the” in paragraph 275-615(1)(c) to correct the grammatical error.

Therapeutic Goods (Medical Devices) Regulations 2002, Compilation No. 63, Registration Date: 12 July 2024 [F2024C00570]

Regulation 11.77 (second occurring)

Kind of editorial change

Numbering or renumbering of provisions

Details of editorial change

Schedule 2 item 10 of the *Therapeutic Goods Legislation Amendment (2024 Measures No. 2) Regulations 2024* instructs to insert regulations 11.76 and 11.77 in the appropriate position in Division 11.20.

Schedule 1 item 4 of the *Therapeutic Goods Legislation Amendment (Fees and Other Measures) Regulations 2024* instructs to insert Division 11.21 in the appropriate position in Part 11. Division 11.21 contains regulation 11.77.

These amendments result in two regulation 11.77s.

This compilation was editorially changed by renumbering the second occurring regulation 11.77 as regulation 11.78.

Public Health (Tobacco and Other Products) Act 2023, Compilation No. 1, Registration Date: 5 July 2024 [C2024C00259]

Paragraph 163C(d)

Kind of editorial change

Change to punctuation

Details of editorial change

Paragraph 163C(d) ends in a full stop despite being followed by paragraph (e).

This compilation was editorially changed to omit the full stop at the end of paragraph 163C(d) and substitute a semicolon to bring it into line with legislative drafting practice.

Water Act 2007, Compilation No. 32, Registration Date: 5 July 2024 [C2024C00260]

Paragraph 3(ga)

Kind of editorial change

Give effect to the misdescribed amendment as intended

Details of editorial change

Schedule 3 item 12 of the *Water Amendment (Restoring Our Rivers) Act 2023* provides as follows:

12 After paragraph (3)(g)

Insert:

- (ga) to ensure that the governance of water markets and trading arrangements relating to Basin water resources is appropriate, and that governance measures promote integrity and transparency in water markets; and

This item refers to “**Paragraph (3)(g)**” rather than “**Paragraph 3(g)**”.

This compilation was editorially changed to insert paragraph 3(ga) after paragraph 3(g) to give effect to the misdescribed amendment as intended.

Section 215VA (heading)

Kind of editorial change

Give effect to the misdescribed amendment as intended

Details of editorial change

Schedule 6 item 39 of the *Water Amendment (Restoring Our Rivers) Act 2023* provides as follows:

39 Subsection 215VA(1)

Repeal the heading, substitute:

215VA Inspector-General may issue standards relating to measuring water taken from Basin water resources

This item refers to “**Subsection 215VA(1)**” rather than “**Section 215VA (heading)**”.

This compilation was editorially changed to repeal and substitute the heading to section 215VA to give effect to the misdescribed amendment as intended.

National Redress Scheme for Institutional Child Sexual Abuse (Funders of Last Resort) Declaration 2019, Compilation No. 28, Registration Date: 3 July 2024 [F2024C00541]

Schedule 1 (item 81)

Kind of editorial change

Give effect to the misdescribed amendment as intended

Details of editorial change

Schedule 1 item 1 of the *National Redress Scheme for Institutional Child Sexual Abuse Amendment (Funders of Last Resort) Declaration 2024 (No. 2)* provides as follows:

1 Schedule 1 (item 81, column 2)

Omit ‘House’, substitute ‘Home’.

The word “House” does not appear in the column headed “**Column 2**” of item 81 of Schedule 1. However, the word “House” does appear in the column headed “**Column 1**” of item 81 of Schedule 1.

This compilation was editorially changed to omit “House” and substitute “Home” in the column headed “**Column 1**” of item 81 of Schedule 1 to give effect to the misdescribed amendment as intended.